All In Biotech

Drug Trial Radar · NCT06465810

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,850

Planned (sponsor's estimate)

Start

Jun 25, 2024

Primary completion

Dec 31, 2031

Study completion Dec 31, 2031

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
ICON plc
First posted
Jun 20, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

Conditions

  • Transthyretin Amyloidosis
  • ATTR-CM
  • ATTRv-PN
  • ATTR
  • ATTR-Mixed
  • hATTR

Interventions

  • Treatment of transthyretin (ATTR) amyloidosis in observational study settingDrug

    Data will be collected on patients with ATTR amyloidosis in a real-world setting

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demographic characteristics (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  2. Treatment patterns (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  3. Clinical characteristics (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  4. Findings from biopsy (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  5. Findings from Cardiovascular magnetic resonance imaging (CMR) (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  6. Findings from Bone tracer cardiac scintigraphy (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  7. Findings from Echocardiography (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  8. ECG variables (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  9. Sural nerve and tibial nerve amplitude (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  10. Biomarker results (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  11. Urine test results (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  12. Clinical manifestations (signs and symptoms) of ATTR amyloidosis (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  13. 36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Summary score (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  14. Norfolk Quality of Life-Diabetic Neuropathy total score (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  15. Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  16. New York Heart Association (NYHA) classification (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  17. National Amyloidosis Centre (NAC) ATTR staging or Mayo staging (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  18. Familial amyloid polyneuropathy (FAP) (Coutinho) staging (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  19. Polyneuropathy disability (PND) score (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  20. Left Ventricular Ejection Fraction (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  21. 6-minute walk test (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  22. Charlson comorbidity index (CCI) and CCI components (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  23. Other comorbidities of interest (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  24. Healthcare resource utilization (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
  25. Mortality (overall and in patients initiating a treatment with eplontersen)Time frame: Throughout study follow-up (up to 7 years)
  26. Liver Disease and Live TransplantTime frame: From time of Enrollment for up to 7 Years

Locations

89 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Indianapolis, Indiana · Recruiting

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Kansas City, Missouri · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    New Brunswick, New Jersey · Recruiting

  • Research Site

    Manhasset, New York · Recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Durham, North Carolina · Recruiting

  • Research Site

    Portland, Oregon · Recruiting

  • Research Site

    Danville, Pennsylvania · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Greenville, South Carolina · Recruiting

  • Research Site

    Germantown, Tennessee · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Dallas, Texas · Recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

  • Research Site

    Richmond, Virginia · Recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Milwaukee, Wisconsin · Recruiting

  • Research Site

    Vancouver, British Columbia, Canada · Recruiting

  • Research Site

    Vancouver, British Columbia, Canada · Recruiting

  • Research Site

    Halifax, Nova Scotia, Canada · Recruiting

  • Research Site

    London, Ontario, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Not yet recruiting

  • Research Site

    Rimouski, Quebec, Canada · Not yet recruiting

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.